Previous studies reported that upregulation of SPOCK2 can decrease invasion and metastasis of prostate cancer and endometrial cancer by inhibiting matrix metalloproteinase 2 (MMP2) and membrane-type 1 matrix metalloproteinase (MT1-MMP) (Liu et al., 2019; Ren et al., 2020). Here, MMP2 is linked to prostate carcinoma.